NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 421
(Total Views: 209)
Posted On: 04/12/2022 3:21:57 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection from blood samples that will evidence Tmax, Cmax and AUC. Secondary objectives of the study include extensive subjective evaluations related to throat burn, user experience and more. The design phase of NIC-H22-1 is complete, and test articles are currently being manufactured. Funding NIC-H22-1 with existing capital, the company is optimistic that this larger study will produce positive findings pursuant to those evidenced in its previous 2021 subjective human testing that utilized DehydraTECH-nicotine formulations demonstrating onset of initial nicotine effectiveness in as little as 1.5 to 4 minutes after an oral dose.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection from blood samples that will evidence Tmax, Cmax and AUC. Secondary objectives of the study include extensive subjective evaluations related to throat burn, user experience and more. The design phase of NIC-H22-1 is complete, and test articles are currently being manufactured. Funding NIC-H22-1 with existing capital, the company is optimistic that this larger study will produce positive findings pursuant to those evidenced in its previous 2021 subjective human testing that utilized DehydraTECH-nicotine formulations demonstrating onset of initial nicotine effectiveness in as little as 1.5 to 4 minutes after an oral dose.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)